Netherlands | India | Mexico* | South Africa* | |||||
n | Mean (SD)/% | n | Mean (SD)/% | n | Mean (SD)/% | n | Mean (SD)/% | |
Gender (% female) | 947 | 65.6 | 947 | 81.2 | 140 | 86.4 | 162 | 81.5 |
Age (years) | 947 | 56.8 (15.3) | 942 | 42.9 (12.6) | 131 | 47.7 (12.5) | 163 | 47.7 (12.5) |
RF (% positive) | 942 | 61.4 | 944 | 87.3 | 137 | 80.3 | 164 | 99.4 |
ACPA (% positive) | 886 | 51.5 | 442 | 72.4 | 99 | 60.6 | 91 | 96.7 |
Body mass index | 779 | 26.1 (4.2) | 503 | 26.6 (6.4) | 115 | 33.8 (41.4) | 61 | 28.1 (7.2) |
Cigarette smoking | 879 | 908 | 104 | 151 | ||||
Current | 24.0 | 2.2 | 24.0 | 18.6 | ||||
Past | 36.6 | 0.0 | 3.9 | 8.6 | ||||
Never | 39.4 | 97.8 | 72.1 | 72.8 | ||||
Symptom duration at diagnosis (months) | 947 | 5.3 (4.7) | 947 | 5.8 (4.5) | 141 | 5.3 (2.5) | 154 | 5.4 (2.4) |
DAS | 865 | 3.1 (1.0) | 549 | 3.9 (0.9) | – | – | – | – |
DAS28 | 867 | 5.0 (1.4) | 517 | 6.1 (1.3) | 124 | 5.6 (1.3) | 137 | 5.9 (1.3) |
ESR | 939 | 33.6 (27.1) | 779 | 68.9 (31.2) | 128 | 32.5 (19.3) | 141 | 39.6 (28.7) |
CRP | 935 | 24.3 (33.9) | 779 | 37.4 (38.3) | 99 | 16.6 (26.4) | 143 | 31.5 (44.7) |
VAS patient global (mm) | 875 | 42.0 (25.7) | 656 | 52.3 (18.4) | 136 | 55.6 (26.0) | 156 | 65.6 (22.4) |
*In order to achieve sets of patients with similar symptom duration at baseline, 86 patients from Mexico and 139 patients from South Africa with longest symptom duration were excluded.
ACPA, anti-citrullinated protein antibody; CRP, C-reactive protein; DAS, Disease Activity Score; ESR, erythrocyte sedimentation rate; RA, rheumatoid arthritis; RF, rheumatoid factor; VAS, visual analogue scale.